A 90‐day preclinical toxicological evaluation in rats of a highly purified and concentrated mulberry leaf extract
Journal of Applied Toxicology · 2024
DOI: 10.1002/jat.4644 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Applied Toxicology, 2024. Verfasst von Timothy S Murbach und 4 weiteren Autor:innen. Beteiligte Einrichtung: AIBMR Life Sciences, Inc., Seattle, Washington, USA. Hauptthemen laut MEDLINE: Morus, Plant Extracts, Plant Leaves, No-Observed-Adverse-Effect Level. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Phynova Group Limited, Banbury UK, Phynova Group Limited, Banbury UK and Nestle Health Science, Vevey Switzerland.
Abstract (Originalsprache)
Mulberry (genus Morus ) leaves have long been used as a human food, especially in Asia, and animal feed. More recently, mulberry leaf extracts have been introduced as a convenient way to consume mulberry for non‐nutritional functional effects. Reducose® 5% is an Morus alba leaf extract that has been highly purified and standardized to a content of 5 ± 0.5% 1‐deoxynojirimycin, a naturally present polyhydroxylated piperidine alkaloid analog of D‐glucose. This extract has previously been evaluated in acute and subacute (28‐day) oral toxicity studies in which no adverse effects of the test item were observed in mice or rats, respectively. Due to continued and growing interest in the extract in multinational markets, we have now further investigated potential toxic effects in subchronic (90‐day) oral toxicity study in male and female Han:WIST rats. The test item was administered at doses of 850, 1700, and 2550 mg/kg bw/day, and did not cause adverse effects in clinical signs, body weight development, clinical pathology, gross pathology, or histopathology in comparison to the vehicle‐control group. The no‐observed‐adverse‐effect‐level was determined to be 2550 mg/kg bw/day. These results add to the existing body of both preclinical and clinical work relevant to the safety of the extract and of interest to regulators in various global markets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- AIBMR Life Sciences, Inc., Seattle, Washington, USA.
- Toxi-Coop Zrt., Budapest, Hungary.
ORCID-Profile: Timothy S Murbach
Förderung
- Phynova Group Limited, Banbury UK
- Phynova Group Limited, Banbury UK and Nestle Health Science, Vevey Switzerland
Zitieren
APA
Murbach, T. S., Glávits, R., Endres, J. R., Hirka, G., & Pasics Szakonyiné, I. (2024). A 90‐day preclinical toxicological evaluation in rats of a highly purified and concentrated mulberry leaf extract. Journal of Applied Toxicology. https://doi.org/10.1002/jat.4644
Vancouver
Murbach TS, Glávits R, Endres JR, Hirka G, Pasics Szakonyiné I. A 90‐day preclinical toxicological evaluation in rats of a highly purified and concentrated mulberry leaf extract. Journal of Applied Toxicology. 2024. doi:10.1002/jat.4644
BibTeX
@article{Murbach2024,
author = {Murbach, Timothy S and Glávits, Róbert and Endres, John R and Hirka, Gábor and Pasics Szakonyiné, Ilona},
title = {A 90‐day preclinical toxicological evaluation in rats of a highly purified and concentrated mulberry leaf extract},
journal = {Journal of Applied Toxicology},
year = {2024},
doi = {10.1002/jat.4644}
}
EUVIMED